Oklo
OKLO
$40.18
+5.74%
Oklo Inc. is a pre-revenue nuclear technology company developing liquid-metal fast fission power plants through its Aurora powerhouse product line, with its first commercial unit designed to produce up to 15 megawatts of electricity, alongside a complementary business line selling used nuclear fuel recycling services to the U.S. market. As a small-cap developer with only 205 employees and a market capitalization of roughly $7.5 billion, Oklo occupies a distinct position as a pure-play advanced nuclear design and licensing company rather than an established utility or equipment manufacturer, competing against other small modular reactor developers such as NuScale and X-Energy. The investor narrative has shifted dramatically over the past year: after a period of intense AI-data-center-driven enthusiasm that pushed shares to a 52-week high of $193.84, the stock has collapsed roughly 64% over twelve months and 51% year-to-date as the market reassesses execution risk, with headlines highlighting a landmark 1.2-gigawatt Meta reactor deal in Ohio slated for 2030, the Trump administration's "Project Prometheus" nuclear initiative that named Oklo a winner, and the cancellation of peer Holtec's IPO as a signal of cooling sentiment toward the SMR sector. The core debate now centers on whether Oklo's multi-decade hyperscaler contracts and government backing can bridge the gap to commercialization before cash burn, dilution, and regulatory timelines erode the equity story.…
OKLO
Oklo
$40.18
Related headlines
Investment Opinion: Should I buy OKLO Today?
We assign a Hold rating on OKLO, balancing the high-risk, high-reward nature of a pre-revenue nuclear technology company against its fortress balance sheet and analyst consensus buy rating. The average analyst target of $78.69 implies 107% upside, but this is contingent on successful execution of multi-year projects. The core thesis is that Oklo's government backing and Meta deal provide a credible path to commercialization, but the timeline is long and uncertain.
Supporting evidence includes a debt-to-equity ratio of 0.00098, a current ratio of 49.1, and interest income of $21.3 million in Q1 2026, which provides a cash cushion. However, the company has no revenue, a net loss of $33.1 million in Q1 2026, and negative free cash flow of -$153.5 million. The valuation is extreme, with a price-to-book of 7.1 and EV-to-sales of 4,061, leaving no margin for error. Analyst estimates project average revenue of $275.9 million, but this is likely years away.
Key risks include regulatory delays, dilution from share issuance (shares up 23.3% YoY), and sector sentiment deterioration. The rating would upgrade to Buy if Oklo secures additional binding contracts and demonstrates progress toward licensing, or if the stock drops below $30 (near 52-week low) with no change in fundamentals. It would downgrade to Sell if the Meta deal is canceled or if cash burn accelerates without new financing. Relative to its history and peers, OKLO is overvalued on current metrics but may be fairly valued if future revenue materializes.
Sign up to view all
OKLO 12-Month Price Forecast
Oklo presents a high-risk, high-reward opportunity with a neutral stance due to the binary nature of its investment case. The company's fortress balance sheet and government backing are offset by zero revenue, massive cash burn, and an extreme valuation. The Meta deal and Project Prometheus are potential game-changers, but execution and regulatory risks are substantial. We would upgrade to bullish if Oklo secures additional binding contracts and demonstrates clear progress toward licensing, or downgrade to bearish if cash burn accelerates or the Meta deal falters. The risk/reward is balanced at current levels, with the stock likely to remain volatile.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oklo's 12-month outlook, with a consensus price target around $78.69 and implied upside of +95.8% versus the current price.
Average Target
$78.69
0 analysts
Implied Upside
+95.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$14 - $130
Analyst target range
Bulls vs Bears: OKLO Investment Factors
The bear case currently has stronger evidence due to Oklo's pre-revenue status, massive cash burn, and extreme valuation multiples that are disconnected from fundamentals. The stock's 64% one-year decline and 51% YTD drop reflect a market that is repricing execution risk and sector-wide sentiment deterioration. However, the bull case rests on transformative catalysts: the Meta 1.2 GW deal, Project Prometheus government backing, and a fortress balance sheet with zero debt. The single most important tension is whether Oklo can bridge the multi-year gap to commercialization before cash burn and dilution erode the equity story. If the company secures additional binding contracts and hits regulatory milestones, the stock could re-rate sharply; if delays or funding challenges emerge, further downside is likely.
Bullish
- Meta 1.2 GW deal validates technology: Oklo's landmark 1.2-gigawatt reactor deal with Meta in Ohio provides third-party validation of its Aurora powerhouse technology and a marquee reference customer. The deal, slated for 2030, underpins the commercial pipeline and could attract additional hyperscaler contracts.
- Project Prometheus government backing: The Trump administration's 'Project Prometheus' nuclear initiative named Oklo a winner, while peer NuScale was excluded. This government support could accelerate licensing, provide funding, and de-risk the regulatory pathway.
- Fortress balance sheet with zero debt: Oklo carries virtually no debt (debt-to-equity of 0.00098) and a current ratio of 49.1, indicating ample liquidity to fund operations. Interest income of $21.3 million in Q1 2026 partially offsets cash burn.
- Analyst consensus buy with 107% upside: 21 analysts rate OKLO a 'buy' with an average target price of $78.69, implying 107% upside from the current $38.00. The high target of $130 suggests significant optionality if execution milestones are met.
Bearish
- Catastrophic 64% one-year decline: OKLO shares have collapsed 63.8% over the past year and 51.2% year-to-date, massively underperforming the S&P 500's 15.0% and 11.7% gains respectively. The stock sits just 10.5% above its 52-week low of $34.38, reflecting deep investor pessimism.
- No revenue and massive cash burn: The company reported $0 revenue in Q1 2026 and a net loss of $33.1 million, with trailing free cash flow of -$153.5 million. With no meaningful top line, Oklo relies entirely on external financing to fund operations.
- Extreme valuation with no earnings: OKLO trades at a price-to-book of 7.1 and an EV-to-sales of 4,061, despite having zero revenue. The forward PE is -37.6, and the PEG ratio is -2.78, indicating the valuation is disconnected from current fundamentals.
- Dilution risk from share count growth: Shares outstanding increased from 138.1 million in Q1 2025 to 170.3 million in Q1 2026, a 23.3% year-over-year increase. Continued equity issuance to fund cash burn will further dilute existing shareholders.
OKLO Technical Analysis
Beta
1.20
1.20x market volatility
Max Drawdown
-79.5%
Largest decline past year
52-Week Range
$34-$194
Price range past year
Annual Return
-70.3%
Cumulative gain past year
| Period | OKLO Return | S&P 500 |
|---|---|---|
| 1m | -4.5% | +1.0% |
| 3m | -29.7% | +5.4% |
| 6m | -27.3% | +17.8% |
| 1y | -70.3% | +16.5% |
| ytd | -48.4% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OKLO Fundamental Analysis
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-153481000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OKLO Overvalued?
PE
-99.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-88.6x
Enterprise Value Multiple
Investment Risk Disclosure
Oklo faces significant financial and operational risks as a pre-revenue company with no current revenue and a Q1 2026 net loss of $33.1 million. Trailing free cash flow is -$153.5 million, and with only $0 revenue, the company is entirely dependent on external financing. The share count has grown 23.3% year-over-year to 170.3 million shares, indicating dilution that will continue as long as cash burn persists. Additionally, the company's first commercial Aurora unit is designed for only 15 MWe, while the Meta deal calls for 1.2 GW, highlighting a massive scale-up execution risk.
Market and competitive risks are elevated given Oklo's extreme valuation (EV-to-sales of 4,061) and a beta of 1.195, which implies higher volatility than the broader market. The SMR sector is highly competitive, with peers like NuScale and X-Energy also vying for contracts, and Holtec's canceled IPO signals cooling investor sentiment. Regulatory hurdles remain a major overhang, as the NRC licensing process for advanced reactors is untested and could cause delays. Furthermore, Oklo's stock has a short ratio of 3.26, indicating that short sellers are actively betting against the company, which could exacerbate downward moves.
The worst-case scenario for Oklo involves a chain of events where regulatory delays push the first Aurora deployment beyond 2030, the Meta deal falls through or is renegotiated, and the company is forced to raise equity at depressed prices, leading to massive dilution. In this scenario, the stock could retest its 52-week low of $34.38, representing a 9.5% decline from the current $38.00, or fall further to the analyst low target of $14.00, a 63.2% drop. Given the max drawdown of -79.55% over the past year, investors could lose more than half their capital if sentiment sours further.
FAQ
The most severe risk is regulatory delay, as the NRC licensing process for advanced reactors is untested and could push commercialization beyond 2030. Financial risk is also high, with no revenue, a net loss of $33.1 million in Q1 2026, and negative free cash flow of -$153.5 million, necessitating further dilution (shares up 23.3% YoY). Competitive risk exists from peers like NuScale and X-Energy, and sector sentiment could deteriorate further, as seen with Holtec's canceled IPO. Finally, macro risk includes a beta of 1.195, making the stock more volatile than the market.
Our 12-month forecast has a base case (50% probability) of $60-$80, assuming steady progress on reactor development and no major setbacks. The bull case (25% probability) targets $100-$130 if regulatory milestones are met and additional contracts are signed. The bear case (25% probability) targets $14-$34 if delays occur and the Meta deal falters. The most likely scenario is the base case, hinging on Oklo maintaining its commercialization timeline and securing financing without excessive dilution.
OKLO appears significantly overvalued on current fundamentals, trading at a price-to-book of 7.1 and an EV-to-sales of 4,061 despite having zero revenue. The forward PE is -37.6, and the PEG ratio is -2.78, indicating that the valuation is not supported by earnings or growth metrics. However, if the company successfully commercializes its reactors and achieves projected revenue of $275.9 million, the valuation could become more reasonable. The market is pricing in substantial future growth, leaving little margin for error.
OKLO is a high-risk, high-reward speculative buy for investors who can tolerate volatility and have a long time horizon. The stock trades at $38.00, with analysts' average target of $78.69 implying 107% upside, but it has no revenue and burns $153.5 million annually. The biggest downside risk is a retest of the 52-week low of $34.38 or the analyst low target of $14.00, representing a 63% loss. For risk-averse investors, it is not a good buy; for those seeking exposure to advanced nuclear, it could be a small position in a diversified portfolio.
OKLO is suitable only for long-term investors with a minimum holding period of 5-10 years, as the company is years away from meaningful revenue and profitability. The stock is highly volatile (beta 1.195) and has no dividend, making it unsuitable for short-term trading or income-focused portfolios. Earnings visibility is low, with no revenue and negative EPS, so investors must be willing to endure significant drawdowns (max drawdown -79.55%) while waiting for commercialization.